Last reviewed · How we verify
Regaine
At a glance
| Generic name | Regaine |
|---|---|
| Sponsor | Energenesis Biomedical Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Androgenic Alopecia TH07 Clinical Trial (PHASE3)
- Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer (EARLY_PHASE1)
- Topical Methotrexate vs Minoxidil for Localized Alopecia Areata (PHASE4)
- Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia (PHASE3)
- Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia (PHASE2)
- A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors (PHASE2)
- Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia (NA)
- Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Regaine CI brief — competitive landscape report
- Regaine updates RSS · CI watch RSS
- Energenesis Biomedical Co., Ltd. portfolio CI